Preclinical study of treatment response in HCT-116 cells and xenografts with 1H-decoupled 31P MRS

NMR in Biomedicine

Volumn 24, Issue 9, 2011, Pages 1159-1168

  Darpolor, Moses M ^a   Kennealey, Peter T ^a   Le, H Carl ^a   Zakian, Kristen L ^a   Ackerstaff, Ellen ^a   Rizwan, Asif ^a   Chen, Jin Hong ^a   Sambol, Elliot B ^a   Schwartz, Gary K ^a   Singer, Samuel ^a   Koutcher, Jason A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

1H decoupled 31P MRS; Apoptosis; Choline kinase; Colon cancer; Flavopiridol; Irinotecan

Indexed keywords

1H-DECOUPLED 31P MRS; CHOLINE KINASE; COLON CANCER; FLAVOPIRIDOL; IRINOTECAN;

ANIMAL CELL CULTURE; CELL DEATH; ENZYMES; MAGNETIC RESONANCE; MAGNETIC RESONANCE SPECTROSCOPY; MAMMALS; METABOLISM; PHOSPHORUS; PHOSPHORYLATION; TUMORS;

BIOLOGICAL MATERIALS;

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CHOLINE KINASE; FLAVOPIRIDOL; IRINOTECAN; PHOSPHATE; PHOSPHORYLCHOLINE; RAS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL STRAIN HCT116; CONTROLLED STUDY; ENZYMATIC ASSAY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LONGITUDINAL STUDY; MOUSE; NONHUMAN; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SACCHAROMYCES CEREVISIAE; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CAMPTOTHECIN; CELL CYCLE; CHOLINE KINASE; CHOLINE-PHOSPHATE CYTIDYLYLTRANSFERASE; COLORECTAL NEOPLASMS; FEMALE; FLAVONOIDS; HCT116 CELLS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; PHOSPHORUS ISOTOPES; PIPERIDINES; PROTONS; SACCHAROMYCES CEREVISIAE; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 80054068153     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1674     Document Type: Article

References (48)

1. Shah MA, Kortmansky J, Motwani M, Drobnjak M, Gonen M, Yi S, Weyerbacher A, Cordon-Cardo C, Lefkowitz R, Brenner B, O'Reilly E, Saltz L, Tong W, Kelsen DP, Schwartz GK. A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopirodol. Clinical Cancer Research 2005; 11(10): 3836-3845.
2. Motwani M, Jung C, Sirotnak FM, She Y, Shah MA, Gonen M, Schwartz GK. Augmentation of Apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts. Clin Cancer Res 2001; 7(12): 4209-4219.
3. Blankenberg FG, Katsikis PD, Storrs RW, Beaulieu C, Spielman D, Chen JY, Naumovski L, Tait JF. Quantitative analysis of apoptotic cell death using proton nuclear magnetic resonance spectroscopy. Blood 1997; 89(10): 3778-3786.
4. Al-Saffar NMS, Troy H, Ramirez de Molina A, Jackson LE, Basetti M, Griffiths JR, Leach MO, Workman P, Lacal JC, Judson IR, Chung Y-L. Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Research 2006; 66(1): 427-434.
5. 31P NMR spectroscopy. NMR in Biomedicine 1989; 1(4): 117-183.
6. Levitt MH, Freeman R. Composite Pulse Decoupling. J Magn Reson 1981; 43: 65-80.
7. Levitt MH, Freeman R, Frenkiel T. Broadband Heteronuclear Decoupling. J Magn Reson 1982; 47: 328-330.
8. Levitt MH, Freeman R, Frenkiel T. Supercycles For Broadband Heteronuclear Decoupling. J Magn Reson 1982; 50: 157-160.
9. Shaka AJ, Keeler J, Freeman R. Evaluation of a new broadband decoupling sequence: WALTZ-16. Journal of Magnetic Resonance 1983; 53(2): 313-340.
10. Andrew ER, Bradbury A, Eades RG. Removal of dipolar broadening of nuclear magnetic resonance spectra of solids by specimen rotation. Nature 1959; 183: 1802-1803.
11. Cheng LL, Ma MJ, Becerra L, Ptak T, Tracey I, Lackner A, Gonzalez RG. Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. Proc Natl Acad Sci USA 1997; 94(12): 6408-6413.
12. Pelech SL, Vance DE. Regulation of phosphatidylcholine biosynthesis. Biochim BiophysActa 1984; 779(2): 217-251.
13. Podo F. Tumour phospholipid metabolism. NMR Biomed 1999; 12(7): 413-439.
14. Ackerstaff E, Glunde K, Bhujwalla ZM. Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem 2003; 19(3): 525-533.
15. Glunde K, Serkova NJ. Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics 2006; 7(7): 1109-1123.
16. Plathow C, Weber WA. Tumor Cell Metabolism Imaging. Journal of Nuclear Medicine 2008; 49(6): 43S-63S.
17. Albright CD, Liu R, Bethea TC, Da Costa K-A, Salganik RI, Zeisel SH. Choline deficiency induces apoptosis in SV40-immortalized CWSV-1 rat hepatocytes in culture. FASEB J 1996; 10(4): 510-516.
18. Cui Z, Houweling M. Phosphatidylcholine and cell death. Biochim Biophys Acta 2002; 1585(2-3): 87-96.
19. Cui Z, Houweling M, Chen MH, Record M, Chap H, Vance DE, Terce F. A genetic defect in phosphatidylcholine biosynthesis triggers apoptosis in Chinese hamster ovary cells. J Biol Chem 1996; 271(25): 14668-14671.
20. Yen C-LE, Mar M-H, Meeker RB, Fernandes A, Zeisel SH. Choline defiency induces apoptosis in primary cultures of fetal neurons. FASEB J 2001; 15(10): 1704-1710.
21. Yen C-LE, Mar M-H, Zeisel SH. Choline deficiency-induced apoptosis in PC12 cells is associated with diminished membrane phosphatidylcholine and sphingomyelin, accumulation of ceramide and diacylglycerol, and activation of caspase. FASEB J 1999; 13(1): 135-142.
22. Kent C, Carman GM. Interactions among pathways for phosphatidylcholine metabolism, CTP synthesis and secretion through the Golgi apparatus. Trends Biochem Sci 1999; 24(4): 146-150.
23. Carman GM, Henry SA. Phospholipid biosynthesis in the yeast Saccharomyces cerevisiae and interrelationship with other metabolic processes. Prog Lipid Res 1999; 38(5-6): 361-399.
24. Yu Y, Sreenivas A, Ostrander DB, Carman GM. Phosphorylation of Saccharomyces cerevisiae choline kinase on Ser30 and Ser85 by protein kinase A regulates phosphatidylcholine synthesis by the CDP-choline pathway. J Biol Chem 2002; 277(38): 34978-34986.
25. Kent C. Eukaryotic phospholipid biosynthesis. Annu Rev Biochem 1995; 64: 315-343.
26. McMaster CR, Bell RM. Phosphatidylcholine biosynthesis via the CDP-choline pathway in Saccharomyces cerevisiae. Multiple mechanisms of regulaion. J Biol Chem 1994; 269(20): 14776-14783.
27. Hernandez-Alcoceba R, Saniger L, Campos J, Nunez MC, Khaless F, Gallo MA, Espinosa A, Lacal JC. Choline kinase inhibitors as a novel approach for antiproliferative drug design. Oncogene 1997; 15(19): 2289-2301.
28. Ramirez de Molina A, Penalva V, Lucas L, Lacal JC. Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K. Oncogene 2002; 21(6): 937-946.
29. Hernandez-Alcoceba R, Fernandez F, Lacal JC. In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. Cancer Research 1999; 59(13): 3112-3118.
30. Okada F, Rak JW, St. Croix B, Lieubeau B, Kaya M, Roncari L, Shirasawa S, Sasazuki T, Kerbel RS. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma. Proc Natl Acad Sci USA 1998; 95(7): 3609-3614.
31. Ambrosini G, Seelman SL, Qin L-X, Schwartz GK. The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner. Cancer Res 2008; 68(7): 2312-2320.
32. Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor Measurement in the Nude Mouse. Journal of Surgical Oncology 1986; 31(4): 229-234.
33. Goteti K, Garner CE, Utley L, Dai J, Ashwell S, Moustakas DT, Gonen M, Schwartz GK, Kern SE, Zabludoff S, Brassil PJ. Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents. Cancer Chemother Pharmacol 2010; 66(2): 245-254.
34. Ballon D, Mahmood U, Jakubowski A, Koutcher JA. Resolution Enhanced NMR Spectroscopy in Biolgical Systems via Magnetic Susceptibility Matched Sample Immersion Chambers. Magn Reson Med 1993; 30(6): 754-758.
35. Chen J-H, Enloe BM, Weybright P, Campbell N, Dorfman D, Fletcher CD, Cory DG, Singer S. Biochemical Corrfelates of Thiazolidinedione-Induced Adipocyte Differentiation by High-Resolution Magic Angle Spinning NMR Spectroscopy. Magn Reson Med 2002; 48(4): 602-610.
36. Adosraku RK, Choi GTY, Constantinou-Kokotos V, Anderson MM, Gibbons WA. NMR lipid profiles of cells, tissues, and body fluids: proton NMR analysis of human erythrocyte lipids. J Lipid Res 1994; 35(11). 1925-1931.
37. McGahon AJ, Martin SJ, Bissonnette RP, Mahboubi A, Shi Y, Mogil RJ, Nishioka WK, Green DR. The end of the (cell) line: Methods for the study of apoptosis in vitro Methods in Cell Biology. 1995; 46: 153-181.
38. Foyer C, Walker D, Spencer C, Mann B. Observations on the phosphate status and intracellular pH of intact cells, protoplasts and chloroplasts from photosynthetic tissue using phosphorus-31 nuclear magnetic resonance. Biochem J 1982; 202(2): 429-434.
39. 31P-nuclear resonance spectroscopy. Eur J Appl Physiol 1994; 69: 465-473.
40. Muruganandham M, Alfieri AA, Matei C, Chen Y, Sukenick G, Schemainda I, Hasmann M, Saltz LB, Koutcher JA. Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled 31P magnetic resonance spectroscopy. Clin Cancer Res 2005; 11(9): 3503-3513.
41. Griffiths JR, Stevens AN, Iles RA, Gordon RE, Shaw D. 31P-NMR investigation of solid tumours in the living rat. Bioscience Reports 1981; 1(4): 319-325.
42. Stubbs M, Bashford CL, Griffiths JR. Understanding the tumor metabolic phenotype in the genomic era. Curr Mol Med 2003; 3(1): 49-59.
43. De Azevedo WF Jr, Mueller-Dieckmann H-J, Schulze-Gahmen U, Worland PJ, Sausville E, Kim S-H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci USA 1996; 93(7): 2735-2740.
44. Aklilu M, Kindler HL, Donehower RC, Mani S, Vokes EE. Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol 2003; 14: 1270-1273.
45. Sedlacek HH. Mechanisms of action of flavopiridol. Crit Rev Oncol Hematol 2001; 38(2): 139-170.
46. Bible KC, Kaufmann SH. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Research 1996; 56(21): 4856-4861.
47. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000; 96(2): 393-397.
48. Wittmann S, Bali P, Donapaty S, Nimmanapalli R, Guo F, Yamaguchi H, Huang M, Jove R, Wang HG, Bhalla K. Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Research 2003; 63(1): 93-99.